Understanding the 10.54% Volatility Levels of Emergent Biosolutions Inc’s (EBS) Stock in the Past 30 Days

The stock of Emergent Biosolutions Inc (EBS) has gone down by -4.71% for the week, with a -26.66% drop in the past month and a -10.23% drop in the past quarter. The volatility ratio for the week is 9.37%, and the volatility levels for the past 30 days are 10.54% for EBS. The simple moving average for the last 20 days is -9.14% for EBS stock, with a simple moving average of -36.66% for the last 200 days.

Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?

The 36-month beta value for EBS is also noteworthy at 1.20. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for EBS is 50.07M, and at present, short sellers hold a 9.81% of that float. The average trading volume of EBS on April 03, 2024 was 3.10M shares.

EBS) stock’s latest price update

Emergent Biosolutions Inc (NYSE: EBS)’s stock price has increased by 7.64 compared to its previous closing price of 2.16. However, the company has seen a -4.71% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-07 that Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Analysts’ Opinion of EBS

Many brokerage firms have already submitted their reports for EBS stocks, with The Benchmark Company repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to The Benchmark Company is $5 based on the research report published on March 07, 2024 of the current year 2024.

EBS Trading at 1.72% from the 50-Day Moving Average

After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.99% of loss for the given period.

Volatility was left at 10.54%, however, over the last 30 days, the volatility rate increased by 9.37%, as shares sank -31.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.27% upper at present.

During the last 5 trading sessions, EBS fell by -4.51%, which changed the moving average for the period of 200-days by -71.20% in comparison to the 20-day moving average, which settled at $2.51. In addition, Emergent Biosolutions Inc saw -3.13% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 1,830 shares at the price of $8.35 back on Jun 02 ’23. After this action, Zoon Kathryn C now owns 49,971 shares of Emergent Biosolutions Inc, valued at $15,280 using the latest closing price.

Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 1,700 shares at $8.38 during a trade that took place back on May 25 ’23, which means that Zoon Kathryn C is holding 51,801 shares at $14,246 based on the most recent closing price.

Stock Fundamentals for EBS

Current profitability levels for the company are sitting at:

  • -0.69 for the present operating margin
  • 0.31 for the gross margin

The net margin for Emergent Biosolutions Inc stands at -0.72. The total capital return value is set at -0.61. Equity return is now at value -74.34, with -30.28 for asset returns.

Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 1.33. The interest coverage ratio of the stock is -8.2.

Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at -8.71. When we switch over and look at the enterprise to sales, we see a ratio of 0.85. The receivables turnover for the company is 5.5for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.


In summary, Emergent Biosolutions Inc (EBS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts